EQ-5D in skin conditions: an assessment of validity and responsiveness

European Journal of Health Economics

Volumn 16, Issue 9, 2015, Pages 927-939

  Yang, Yaling ^a   Brazier, John ^b   Longworth, Louise ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

EQ 5D; Responsiveness; Skin conditions; Validity

Indexed keywords

ACNE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL EFFECTIVENESS; CONSTRUCT VALIDITY; CONVERGENT VALIDITY; CORRELATION COEFFICIENT; EUROQOL 5D; HAND ECZEMA; HEALTH UTILITY INDEX 3; HUMAN; LEG ULCER; PATIENT; POPULATION; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RELIABILITY; SHORT FORM 6D; SKIN DISEASE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SUPPURATIVE HIDRADENITIS; SYSTEMATIC REVIEW; VALIDITY; FEMALE; HEALTH STATUS; MALE; PATIENT PREFERENCE; PSYCHOLOGY; PSYCHOMETRY; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; REPRODUCIBILITY;

FEMALE; HEALTH STATUS; HUMANS; MALE; PATIENT PREFERENCE; PSYCHOMETRICS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; REPRODUCIBILITY OF RESULTS; SKIN DISEASES; SURVEYS AND QUESTIONNAIRES;

EID: 84947212050     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-014-0638-9     Document Type: Article

References (39)

1. NICE: NICE Guide to the Methods of Technology Appraisal. NICE, London (2008)
2. NICE: NICE Guide to the Methods of Technology Appraisal. NICE, London (2013)
3. Brooks, R.: EuroQol: the current state of play. Health Policy 37(1), 53–72 (1996)
4. Dolan, P.: Modeling valuations for EuroQol health states. Med. Care 35(11), 1095–1108 (1997)
5. Brazier, J., Roberts, J., Deverill, M.: The estimation of a preference-based measure of health from the SF-36. J. Health Econ. 21(2), 271–292 (2002). pii:S0167-6296(01)00130-8 (published online first)
6. Feeny, D., Furlong, W., Torrance, G.W., et al.: Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med. Care 40(2), 113–128 (2002)
7. Dowie, J.: Decision validity should determine whether a generic or condition-specific HRQOL measure is used in health care decisions. Health Econ. 11(1), 1–8 (2002)
8. Herdman, M., Gudex, C., Lloyd, A., et al.: Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual. Life Res. 20(10), 1727–1736 (2011)
9. Barton, G.R., Bankart, J., Davis, A.C.: A comparison of the quality of life of hearing-impaired people as estimated by three different utility measures. Int. J. Audiol. 44(3), 157–163 (2005)
10. Brazier, J., Roberts, J., Tsuchiya, A., Busschbach, J.: A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 13(9), 873–884 (2004). doi:10.1002/hec.866. [published Online First: Epub Date]
11. Longworth, L., Bryan, S.: An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ. 12(12), 1061–1067 (2003). doi:10.1002/hec.787. (published online first)
12. Brazier, J.E., Rowen, D., Mavranezouli, I., et al.: Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome). Health Technol. Assess. 16(32), 1–114 (2012). doi:10.3310/hta16320. (published online first)
13. Cella, D.F., Tulsky, D.S., Gray, G., et al.: The functional assessment of cancer therapy scale: development and validation of the general measure. J. Clin. Oncol. 11(3), 570–579 (1993)
14. Papaioannou, D., Brazier, J., Parry, G.: How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in schizophrenia? Syst. Rev. Value Health 14(6), 907–920 (2011)
15. Tosh, J., Brazier, J., Evans, P., Longworth, L.: A review of generic preference-based measures of health-related quality of life in visual disorders. Value Health 15(1), 118–127 (2011)
16. Brazier, J. E., Connell, J., Papaioannou, D., et al.: Validating generic preference-based measures of health in mental health populations and estimating mapping functions for widely used specific measures. Health Technol. Assess. (In press)
17. Brazier, J., Deverill, M.: A checklist for judging preference based measures of health related quality of life: learning from psychometrics. Health Econ. 8(1), 41–51 (1999)
18. O’donnell, B.F., Lawlor, F., Simpson, J., Morgan, M., Greaves, M.W.: The impact of chronic urticaria on the quality of life. Br. J. Dermatol. 136(2), 197–201 (1997)
19. Lasek, R.J., Chren, M.M.: Acne vulgaris and the quality of life of adult dermatology patients. Arch. Dermatol. 134(4), 454 (1998)
20. Group, E. (http://www.euroqol.org/eq-5d-references/reference-search.html). Accessed on September 2010
21. Guyatt, G.H., Deyo, R.A., Charlson, M., Levine, M.N., Mitchell, A.: Responsiveness and validity in health status measurement: a clarification. J. Clin. Epidemiol. 42(5), 403–408 (1989)
22. Klassen, A.F.N., Newton, J.N., Mallon, E.: Measuring quality of life in people referred for specialist care of acne: comparing generic and disease-specific measures. J. Am. Acad. Dermatol. 43(2 I), 229–233 (2000)
23. Van De Kerkhof, P.C.M.: The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. Br. J. Dermatol. 151(3), 663–668 (2004)
24. Bansback, N.J., Ara, R., Barkham, N., et al.: Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology 45, 1029–1038 (2006)
25. Christophers, E., JNWN, B., CEM, G., et al.: The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J. Eur. Acad. Dermatol. Venereol. 24(5), 548–554 (2010)
26. Daudén, E., Griffiths, C., Ortonne, J.-P., et al.: Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J. Eur. Acad. Dermatol. Venereol. 23(12), 1374–1382 (2009)
27. Luger, T., Barker, J., Lambert, J., et al.: Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J. Eur. Acad. Dermatol. Venereol. 23(8), 896–904 (2009)
28. Reich, K., Segaert, S., Van de Kerkhof, P., et al.: Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology 219(3), 239–249 (2009)
29. Weiss, S., Kimball, A., Liewehr, D., Blauvelt, A., Turner, M., Emanuel, E.: Quantifying the harmful effect of psoriasis on health-related quality of life. J. Am. Acad. Dermatol. 47(4), 512–518 (2002)
30. Brodszky, V., Péntek, M., Bálint, P., et al.: Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey. Scand. J. Rheumatol. 39(4), 303–309 (2010)
31. Shikiar, R., Willian, M., Okun, M., Thompson, C., Revicki, D.: The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual. Life Outcomes 4, 71 (2006)
32. Revicki, D., Willian, M.K., Saurat, J.-H., et al.: Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br. J. Dermatol. 158(3), 549–557 (2008)
33. Shikiar, R., Heffernan, M., Langley, R., Willian, M., Okun, M., Revicki, D.: Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a Phase II randomized controlled trial. J. Dermatol. Treat. 18(1), 25–31 (2007)
34. Weiss, S.C.R., Rehmus, W., Kimball, A.: An assessment of the cost-utility of therapy for psoriasis. Ther. Clin. Risk Manag. 2(3), 325–328 (2006)
35. Matusiak, L., Bieniek, A., Szepietowski, J.C.: Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 90(3), 264–268 (2010)
36. Moberg, C., Alderling, M., Meding, B.: Hand eczema and quality of life: a population-based study. Br. J. Dermatol. 161(2), 397–403 (2009)
37. Walters, S.J., Morrell, C.J., Dixon, S.: Measuring health-related quality of life in patients with venous leg ulcers. Qual. Life Res. 8(4), 327–336 (1999)
38. Longworth, L., Yang, Y., Young, T., et al.: Use of generic and condition-specific measures of health related quality of life in NICE decision-making. Health Technol. Assess. 18(9), 1–224 (2014)
39. Swinburn, P., Lloyd, A., Boye, K.S., Edson-Heredia, E., Bowman, L., Janssen, B.: Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK. Value Health 16(8), 1156–1162 (2013)